Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4721 EMPEROR BOULEVARD, SUITE 100 DURHAM NC 27703 |
Tel: | N/A |
Website: | https://www.bioventus.com |
IR: | See website |
Key People | ||
Anthony P. Bihl Interim Chief Executive Officer, Director | Mark Singleton Chief Financial Officer, Senior Vice President | Katrina Church Senior Vice President, Chief Compliance Officer |
Anthony D'adamio Senior Vice President, General Counsel | Sharon W. Klugewicz Senior Vice President - Quality and Regulatory Affairs |
Business Overview |
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body's natural healing process. Its portfolio of products is grouped into three verticals: Pain Treatments, Surgical Solutions, and Restorative Therapies. Its Pain Treatments consist of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions consists of bone graft substitutes (BGS) to fuse and grow bones and ultrasonic medical devices used for precise bone sculpting, removal of tumors, and tissue debridement in various surgeries, including spine and neurosurgery. Its Restorative Therapies consist of an ultrasonic bone healing system for fracture care, skin allografts and products used to support the healing of chronic wounds, as well as advanced rehabilitation devices. |
Financial Overview |
For the three months ended 01 April 2023, Bioventus Inc revenues increased 2% to $119.1M. Net loss before extraordinary items increased from $10.9M to $79.7M. Revenues reflect International segment increase of 14% to $15.1M. Higher net loss reflects Impairment of assets increase from $0K to $78.6M (expense), Int exp on Financial Lease Liabilities increase from $1K to $137K (expense). |
Employees: | 1,040 as of Apr 1, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $630.17M as of Apr 1, 2023 |
Annual revenue (TTM): | $513.89M as of Apr 1, 2023 |
EBITDA (TTM): | $72.33M as of Apr 1, 2023 |
Net annual income (TTM): | -$227.09M as of Apr 1, 2023 |
Free cash flow (TTM): | -$0.67M as of Apr 1, 2023 |
Net Debt Last Fiscal Year: | $398.48M as of Apr 1, 2023 |
Shares outstanding: | 78,273,462 as of May 12, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |